A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.
In recent years, Canada and other countries that require justifications for high-priced biologics have begun to shift patients to lower-cost biosimilars, known as nonmedical switching. Biosimilars for infliximab, used in inflammatory bowel disease (IBD), which encompasses Crohn disease (CD) and ulcerative colitis (UC), have become increasingly available.
The inclusion of biosimilars in economic evaluations for pricing decisions has been lacking, but researchers writing in MDM Policy & Access said that examining biologic drug price in a sensitivity analysis provided insight into the cost-effectiveness of biosimilar alternatives.
The authors screened studies using databases such as MEDLINE, Embase, Healthstar, Allied and Complementary Medicine, and more; economic assessments of infliximab for adult or pediatric CD and/or UC published from 1998 through 2019 where drug price was varied in sensitivity analysis were included. Eligible studies could include originator infliximab, biosimilar infliximab, or both, either as an exclusive comparator or used with other therapies; only economic evaluations that contained a 1-way sensitivity analysis of price could be included.
Researchers included each jurisidction’s stated willingness-to-pay threshold for the cost-effectiveness of infliximab.
Out of 844 studies screened, 31 were analyzed. Most studies (58%) showed an incremental cost-effectiveness of infliximab in gastrointestinal diseases that surpassed the WTP threshold.
However, infliximab showed favorable cost-effectiveness at a price ranging from C$66 (US$49) to C$1260 (US$930.13 per vial, depending on the location.
In many other countries, drugs are assessed for their therapeutic benefit relative to existing products, and depending on the outcome of that assessment, price ceilings are set accordingly.
But mandatory switching policies ordering the use of lower cost biosimilars in patients with IBD have incited worries for patients who prefer the original biologic.
The researchers of the current study said alternative pricing strategies and treatment access could be considered to allow patients with IBD to continue access to their current medications.
Reference
Bashir NS, Hughes A, Ungar WJ. Infliximab pricing in international economic evaluations in inflammatory bowel disease to inform biologic and biosimilar access policies: a systematic review. MDM Policy & Practice. Published online February 24, 2023.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.